Home / Community / News

News

10/17/2017 - 3:35pm

After a year of outreach and education, MDF has successfully convinced the Social Security Administration (SSA) to list congenital myotonic dystrophy (CDM) in its Compassionate Allowances program, significantly easing the application and review process.

09/26/2017 - 3:29pm

AMO Pharma released interim results for a Phase 2a safety and toxicity study of Tideglusib (also known as AMO-02) for adolescents and adults with congenital myotonic dystrophy.

09/18/2017 - 11:00am

New data is available on the frequency, progression and treatment of GI symptoms in DM1 and DM2.

09/18/2017 - 10:49am

A new review article assesses the current status of and recommends future directions for brain imaging studies in DM1.

09/18/2017 - 10:41am

Given the brain manifestations of DM1, how aware are most patients of the impact and progression of their disease?

Partners

© Myotonic Dystrophy Foundation. All rights reserved.